Taconic Biosciences News

Local Production of Critical Immuno-oncology Models Now Available in Europe Rensselaer, NY — February 14, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces its humanized immune system mice models are now being produced in Europe. Local production provides European drug discovery researchers with easier access to this critical oncology research tool. Humanized immune system mice enable drug discovery research by...  Read More

Expands and Broadens Taconic Biosciences' Immuno-oncology Portfolio Application Rensselaer, NY — January 31, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, expands its premier immuno-oncology portfolio with the launch of the new B2m-NOG mouse model. Immuno-oncology leverages the body's immune system to fight cancer, increasing the ability to target the disease. Animal models used in this therapeutic development include special mice,...  Read More

New State-of-the-Art Laboratories in Leverkusen, Germany Rensselaer, NY — January 13, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, opened a new model generation facility in Leverkusen, Germany. This location houses model generation services, replacing the previous Taconic site in Cologne, Germany. Custom genetically modified animal models are critical to the drug discovery process. Taconic leads the industry in providing model...  Read More

Local Commercial Animal Model Production and Colony Management Services Available to West Coast Customers Rensselaer, NY — January 2, 2020 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the availability of both commercial animal model production and colony management services through a new location in San Diego. Taconic can now provide critical drug discovery research solutions locally to west coast customers....  Read More

Proven Model Available Exclusively From Taconic Biosciences Rensselaer, NY — November 4, 2019 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, expands its robust neurodegeneration portfolio with the launch of a new Alzheimer's disease model, the ARTE10 mouse model. Exclusively available from Taconic, the ARTE10 is a transgenic mouse model expressing mutant human APP and PS1 genes. This combination manifests in early...  Read More

Dr. Frank Sistare Joins Taconic Biosciences' Scientific Advisory Board Rensselaer, NY — October 17, 2019 - Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the addition of Frank Sistare, PhD to its Scientific Advisory Board (SAB). Dr. Sistare joins existing SAB members Andrew Goodman, PhD, David Hill, PhD, and Robert Rosenthal, PhD. The SAB will continue to collaborate with Taconic's management in...  Read More

The IP landscape surrounding the use of the CRISPR/Cas9 technology (and variants of it) can pose challenges for model generation. In a recent article published in DDN, Taconic Biosciences' Dr. Caroline Horizny explains the various CRISPR/Cas9 patents and the implications of obtaining patent rights when creating a new animal model for preclinical research: "The CRISPR/Cas9 system, and variants of it, allows for in-vivo modifications including gene knockouts,...  Read More

An article recently published in DDN highlights Taconic Biosciences's new diet-induced NASH mouse model and its importance for preclinical liver disease research. The NASH B6 is available commercially off-the-shelf and available immediately for NAFLD and NASH studies. This level of access enables researchers to test and develop new therapeutics sooner, by skipping the twenty-six weeks needed for other mouse models to develop NASH symptoms once placed on...  Read More

Resulting Studies Will Provide Critical Reference Data to Drive Advancements in Human Health Rensselaer, NY — September 3, 2019 - Taconic Biosciences, a global leader in providing genetically engineered animal model solutions, announces its participation in the second Rodent Research Reference (RRR) mission to the International Space Station. Taconic has a history with NASA dating back to 1985. While previous NASA programs were collaborations with academic and/or...  Read More

Two of Taconic Biosciences's newest products are highlighted in a recent article published in Outsourcing-Pharma. The first, TruBIOME™, is a comprehensive solution to increase reproducibility in mouse models through custom microbial associations. The second is the launch of Taconic's new commercial diet-induced NASH mouse model, which will enable researchers to obtain a model faster for preclinical studies: "As summer heated up, the pharmaceutical industry saw major developments...  Read More